thromboplastin and amotosalen

As a pooled donor blood product, cryoprecipitate (cryo) carries risks of pathogen transmission. Pathogen inactivation (PI) improves the safety of cryoprecipitate, but its effects on haemostatic properties remain unclear. This study investigated protein expression in samples of pathogen inactivated cryoprecipitate (PI-cryo) using non-targeted quantitative proteomics and in vitro haemostatic capacity of PI-cryo.. Whole blood (WB)- and apheresis (APH)-derived plasma was subject to PI with INTERCEPT. Over 300 proteins were quantified across paired PI-cryo and controls. PI did not alter the expression of coagulation factors, but levels of platelet-derived proteins and platelet-derived MPs were markedly lower in the WB PI-cryo group. Compared to controls, WB (but not APH) cryo samples demonstrated significantly lower MP prothrombinase activity, prolonged clotting time, and lower clot firmness on thromboelastometry after PI. However, PI did not affect overall thrombin generation variables in either group.. Data from this study suggest that PI via INTERCEPT

Topics: Blood Component Removal; Blood Platelets; Blood Preservation; Blood Proteins; Blood Safety; Blood-Borne Infections; Blood-Borne Pathogens; Cell-Derived Microparticles; Cryopreservation; Furocoumarins; Humans; Microbial Viability; Photochemistry; Photosensitizing Agents; Plasma; Thrombelastography; Thrombin; Thromboplastin; Ultraviolet Rays; Virus Inactivation